No Data
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley Maintains Staar Surgical(STAA.US) With Sell Rating, Cuts Target Price to $23
STAAR Surgical's (NASDAQ:STAA) Earnings Have Declined Over Three Years, Contributing to Shareholders 71% Loss
STAAR Surgical to Participate in BTIG Ophthalmology Day
Implied Volatility Surging for STAAR Surgical (STAA) Stock Options
STAAR Surgical to Participate in Stephens Annual Investment Conference (NASH2024)